Signals Analytics’ COVID-19 Playbook Leverages Advanced Analytics for Accelerating Vaccine Development, Drug Discovery
Free to researchers, the COVID-19 Playbook, built on top of the Signals Analytics platform, highlights critical market intelligence and trends with off-the-shelf taxonomies and visualization tools.
Note: TDWI’s editors carefully choose vendor-issued press releases about new or upgraded products and services. We have edited and/or condensed this release to highlight key features but make no claims as to the accuracy of the vendor's statements.
Signals Analytics, a next-generation advanced analytics platform that leverages external data to uncover trends and predictive insights, has released its COVID-19 Playbook, providing access to critical market intelligence and trends surrounding potential treatments for the novel coronavirus.
As part of their dedication to fighting the virus, Signals Analytics is offering the COVID-19 Playbook at no cost to researchers to help them monitor vaccines that are in development for COVID-19 and other strains of coronavirus, monitor trending drugs being tested for COVID-19, and assess which drugs are being repurposed to help treat infected people.
The COVID-19 Playbook is a front-end user interface of the Signals Analytics platform, powered by advanced analytics, patented natural language processing (NLP) techniques, and taxonomies developed by domain experts with years of academic and pharmaceutical industry experience. It connects data from a wide range of sources including clinical trials, research papers, business events, announcements, media coverage, and drug developments. Context is extracted from the various data types and visualizations and actionable insights are generated.
Like Signals Analytics’ other playbooks, the COVID-19 Playbook is aimed at heads of research, development, and innovation as well as leaders responsible for growth, business development, mergers, and acquisitions looking for ways to accelerate vaccine and drug discovery. The aggregated dashboards address many important business questions such as: what are the leading and emerging targets being analyzed for COVID-19, which are the leading and emerging drugs and vaccines that are being researched and tested, which drugs are being repurposed to treat COVID-19, and which entities are leading and emerging for COVID-19 testing and treatment?
“As the COVID-19 pandemic progresses, a deluge of data is being generated every day and it is impossible for researchers to keep up,” said Gil Sadeh, CEO of Signals Analytics. “Most other platforms provide insights based on limited data sets or simple reference listings that require the user to input specific search parameters. The Signals Analytics platform, on the other hand, is designed to surface trends and actionable insights across a wide range of data sets to alleviate the burden researchers and analysts face as they look for clues that will speed up vaccine development and identify effective treatments. In the middle of this pandemic, every minute counts. We are proud to offer our COVID-19 Playbook to industry leaders, nonprofits and government agencies to turn a very labor-intensive process filled with risk and uncertainty into something actionable and relevant that will speed up the end to this scourge.”
The Playbook is available here.